Taysha Gene Therapies
Market cap $1.30B 326.0M shares (10-Q, Nov 12, 2026) × $4.00 close Nov 17, 2026
Most recent annual filing: 2026-03-19
- Second CNS gene therapy candidate1H 2027Second CNS gene therapy candidate, 1H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
TSHA-113
- Undisclosed indication
TSHA-114
TSHA-120
Discontinued (1)
- TSHA-106 — Angelman Syndrome · discontinued evaluation of TSHA-106 in 2025
Capital (as filed)
- Cash
- $423M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$32.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $423M cash, runway 2H 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-06-25 424B5 · Priced offering 32.5M shares · at $6.00 · $200M gross · 13.5% below the prior close ($6.94, Jun 24, 2026) · incl. pre-funded warrants
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (8)
- 2026-11-13 UPDATE: Taysha Gene Therapies (TSHA) - The Factory Passed 🔒 Paid
- 2026-08-15 UPDATE: Taysha Gene Therapies (TSHA) - Follow the Money, Finally 🔒 Paid
- 2026-08-12 UPDATE: Taysha Gene Therapies (TSHA) - The First Asterisk on a Clean Safety Record 🔒 Paid
- 2026-08-03 UPDATE: Taysha Gene Therapies (TSHA) - The Factory Gets a Landlord 🔒 Paid
- 2026-06-25 UPDATE: Taysha Gene Therapies (TSHA) - The Deal Prints at $6.00 🔒 Paid
- 2026-06-24 UPDATE: Taysha Gene Therapies (TSHA) - The $200M Raise on Strength 🔒 Paid
- 2026-06-22 UPDATE: Taysha Gene Therapies (TSHA) - The Dimmer Switch Holds 🔒 Paid
- 2026-04-25 Taysha Gene Therapies (TSHA) - Scientific Deep Dive for TSHA-102 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (8 calls)
Every verdict Biotech Distilled has published on Taysha Gene Therapies, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-25 Buy core Taysha Gene Therapies (TSHA) - Scientific Deep Dive for TSHA-102 and Pipeline Products Taysha has de-risked the biology with solid video-adjudicated clinical data, secured written FDA alignment on an accelerated BLA pathway, and holds unencumbered global rights to a late-stage gene therapy with strong M&A appeal.
- 2026-06-22 Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Dimmer Switch Holds The 100% response rate held and deepened at N=12 with ≥12 months follow-up, the pivotal trial overenrolled to N=17, and the safety database doubled to N=29 with zero treatment-related SAEs, further de-risking the thesis while the stock remains flat.
- 2026-06-24 Buy core UPDATE: Taysha Gene Therapies (TSHA) - The $200M Raise on Strength The $200M raise-on-strength extends runway through BLA filing and into potential commercial launch, with bulge-bracket bookrunners and launch-prep use of proceeds signaling management conviction; clinical and regulatory thesis fully intact.
- 2026-06-25 Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Deal Prints at $6.00 The offering cleared at the floor of the clean range at $6.00, resolving the financing overhang and funding the company through the BLA-to-launch window; sector sentiment rather than TSHA-specific concerns drove the discount.
- 2026-08-03 Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Factory Gets a Landlord Locking in Catalent as commercial manufacturer at an FDA-licensed AAV facility with no tech transfer required shortens the CMC leg of the bear case while the stock trades below the offering price, widening the asymmetry.
- 2026-08-12 Buy core UPDATE: Taysha Gene Therapies (TSHA) - The First Asterisk on a Clean Safety Record A single Grade 2 resolving peripheral sensory neuropathy adds a small crack to the safety leg of the bear case but does not reprice the thesis given the 100% response rate, fortified balance sheet, and pre-blessed regulatory pathway.
- 2026-08-15 Buy core UPDATE: Taysha Gene Therapies (TSHA) - Follow the Money, Finally RA Capital's 13G/A confirms a fully-loaded post-offering position of ~75.7M shares of economic exposure, answering the smart-money question and reinforcing the asymmetry while the stock trades below the $6.00 offering print on no company-specific news.
- 2026-11-13 Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Factory Passed PPQ completed with all parameters meeting predefined specs and FDA-aligned comparability criteria, retiring the CMC leg of the bear case and enabling potential pooling of Part A data into the BLA, while the stock has fallen 29% on no negative company-specific news.
- Long call · opened Apr 27, 2026 at $6.46 · -38.1% vs XBI +9.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseTaysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe PPQ manufacturing campaign — the gating CMC item I've flagged in every update since June — just passed, with all commercial batches meeting predefined specs and comparability criteria. Meanwhile the stock has drifted to $4.21, further below the $6.00 offering print, with the market seemingly unaware that the factory just delivered.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseTaysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
- Oct 1, 2026ReleaseTaysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual MeetingBD extracted 1 program update from this document → TSHA pipeline
- Aug 11, 2026ReleaseTaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → TSHA pipeline
- Aug 11, 202610-QQuarterly report
- Aug 4, 2026ReleaseTaysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
- Aug 3, 2026ReleaseTaysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
- Jun 25, 2026ReleaseTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingBD extracted 1 program update from this document → TSHA pipeline
- Jun 25, 20268-KCurrent report: material agreement, other events · EX-99.1
- Jun 25, 2026424B5Prospectus supplement (offering)
- Jun 24, 2026ReleaseTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Jun 24, 2026ReleaseTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Jun 24, 2026424B5Prospectus supplement (offering)
- Jun 22, 2026ReleaseTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett SyndromeBD extracted 1 program update from this document → TSHA pipeline
- Jun 22, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → TSHA pipeline
- Jun 2, 20268-KCurrent report: shareholder vote
- May 6, 20268-KCurrent report: results of operations · EX-99.1
- May 6, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Mar 19, 20268-KCurrent report: results of operations · EX-99.1
- Mar 19, 202610-KAnnual report
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 22, 2026ARSAnnual report to shareholders